Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTI164 in young people with Autism Spectrum Disorder
NCT05626959Phase 3Completed
- Sponsor
- Fenix Innovation Group
- Start
- Nov 2022
- Primary completion
- Mar 2024
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing NTI164 with Placebo (2 arms). Primary endpoint: Clinical Global Impression-Severity at Week 8. Started Nov 2022; status: completed.
02
Drugs
NTI164
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05626959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626959.